MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach

MAIA (NYSE:MAIA) announced progress for its telomere-targeting candidate ateganosine as a potential new class for advanced non-small cell lung cancer (NSCLC) on Dec 10, 2025.

Rhea-AI Summary

MAIA (NYSE:MAIA) announced progress for its telomere-targeting candidate ateganosine as a potential new class for advanced non-small cell lung cancer (NSCLC) on Dec 10, 2025. MAIA said ateganosine has received FDA Fast Track designation for NSCLC patients resistant to immunotherapy and chemotherapy and that it is initiating a Phase 3 THIO-104 trial.

The release highlights market context and figures: the CPI category generated about $50B in 2024, NSCLC market value cited at $34.1B now and projected to $68.8B by 2033, ~180,000 U.S. NSCLC patients entering treatment annually, and Keytruda revenue of $29.5B in 2024. Ateganosine also holds FDA orphan drug designations for glioblastoma, HCC, and SCLC, each conferring seven years of U.S. exclusivity if approved.

Positive

• FDA Fast Track designation for ateganosine in NSCLC
• Initiation of Phase 3 THIO-104 trial
• Orphan drug designations for glioblastoma, HCC, and SCLC (7-year U.S. exclusivity if approved)

Negative

• CPI market concentration with Keytruda dominance ($29.5B in 2024) creates strong incumbent competition
• Biosimilar entrants expected from 2028 could pressure CPI pricing before market maturation

Argus Dec 10 session

+2.22% close to close Open Argus

Details

News Market Reaction – MAIA

On Dec 10, the day this news came out, MAIA closed 2.22% above the previous close.

Data tracked by StockTitan Argus for the Dec 10 session.

Market Context

This announcement frames ateganosine within a large NSCLC and broader oncology opportunity, highligh...

Analysis

This announcement frames ateganosine within a large NSCLC and broader oncology opportunity, highlighting CPI market size of about $50B and an NSCLC market projected to reach $68.8B by 2033. It reiterates Fast Track status, pending Phase 3 initiation, and multiple FDA Orphan Drug Designations. Investors may focus on upcoming efficacy and survival data, trial enrollment progress, and how telomerase targeting in >80% of tumors translates into clinically meaningful benefit.

Key Figures

CPI NSCLC sales 2024: $50 billion NSCLC CPI share: >30% Keytruda 2024 revenue: $29.5 billion +5 more

CPI NSCLC sales 2024

$50 billion

Global checkpoint inhibitor category sales in 2024

NSCLC CPI share

>30%

Portion of all NSCLC drug sales from checkpoint inhibitors

Keytruda 2024 revenue

$29.5 billion

Keytruda revenue in 2024, with NSCLC ~30% of sales

Keytruda 2027 outlook

$35 billion

Keytruda revenue expected by 2027 before biosimilars

Tumors with telomerase

>80%

Human tumors with telomerase activity targeted by ateganosine

NSCLC market 2025

$34.1 billion

Current NSCLC market size cited in article

NSCLC 2033 projection

$68.8 billion

Projected NSCLC market size by 2033

US NSCLC patients

180,000 per year

Patients entering U.S. NSCLC treatment ecosystem annually

Historical Context

5 past events · Latest: Dec 01

5 events

1. Dec 01

   Insider buying & data

   24h Move

   +1.7%

   CEO and directors bought shares; THIO-101 showed 38% response and 17.8-month OS.

2. Nov 21

   Clinical update

   24h Move

   +4.7%

   SITC 2025 updates on THIO-101 and THIO-104, Fast Track status, and survival data.

3. Nov 20

   Conference presentation

   24h Move

   -5.3%

   CEO presented 38% response vs ~6% third-line benchmark and Fast Track pursuit.

4. Oct 27

   Trial-in-progress poster

   24h Move

   +4.9%

   AACR-NCI-EORTC poster with early Part C enrollment and consistent safety profile.

5. Oct 23

   Survival update

   24h Move

   +7.3%

   ESMO data highlighting a THIO-101 patient with 30-month survival in NSCLC.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-small cell lung cancer, checkpoint inhibitors, immunotherapies, telomerase, +4 more

8 terms

non-small cell lung cancer medical

"The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing"

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

checkpoint inhibitors medical

"After a decade of targeted therapies and checkpoint inhibitors (CPIs) dominating"

Checkpoint inhibitors are drugs that help the immune system recognize and attack cancer cells by blocking certain proteins that normally keep immune responses in check. They act like brakes being released on the immune system, allowing it to target tumors more effectively. These medicines are important for investors because they represent a promising area of cancer treatment with growing research, development, and commercial potential.

immunotherapies medical

"Unlike targeted therapies requiring EGFR, ALK, KRAS, or other mutations—and unlike immunotherapies dependent on PD-1/PD-L1"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

telomerase medical

"designed to exploit a universal feature of cancer cells: telomerase activity, present in more than 80%"

Telomerase is an enzyme that rebuilds the protective caps at the ends of chromosomes (called telomeres), like someone repairing the plastic tips on shoelaces so they don’t fray. It matters to investors because drugs that boost or block telomerase can affect aging-related conditions and many cancers, making them high-impact targets for biotech development, clinical trial results, and company valuations.

fast track designation regulatory

"MAIA was recently awarded Fast Track Designation by the U.S. FDA for the treatment"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

orphan drug designations regulatory

"The candidate already carries FDA Orphan Drug Designations (ODDs) for: Glioblastoma"

A regulatory status granted to medicines that treat rare diseases, giving developers special incentives and protections — for example, reduced fees, tax benefits, and a period of exclusive marketing once approved. Think of it as a government “boost” that lowers development costs and shields a product from direct competition for a time; investors watch for it because it can raise a drug’s commercial value and reduce the financial risk of bringing a treatment for a small patient group to market.

biosimilars regulatory

"Keytruda is expected to approach $35 billion by 2027—just before biosimilars begin entering"

Biosimilars are medicines made to be highly similar to an already approved biological drug produced from living cells, with no meaningful differences in safety or effectiveness. They matter to investors because they introduce lower‑cost competition to expensive biologic treatments—similar to how generic drugs compete with brand drugs—but involve more complex manufacturing, regulatory review and patent risk, which can affect market share, pricing and profit margins across the sector.

chemotherapy medical

"patients without actionable mutations and who no longer respond to CPIs or chemotherapy."

Chemotherapy is the use of drugs to kill or slow the growth of cancer cells, typically given as pills or intravenous infusions; because these drugs target rapidly dividing cells they can also harm healthy tissue and cause side effects. It matters to investors because clinical trial results, regulatory approvals, pricing and insurance coverage directly affect a drugmaker’s sales, hospital treatment patterns and overall healthcare spending—much like a new product that can change a company’s market share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted therapies and checkpoint inhibitors (CPIs) dominating headlines, MAIA believes that a new therapeutic class—telomere-targeting agents—is emerging for the population with substantial unmet medical need: patients without actionable mutations and who no longer respond to CPIs or chemotherapy.

This is a segment that existing therapies leave behind. And it is the segment where we believe that ateganosine, developed by MAIA, may soon become one of the most consequential entrants in years.

A Market Dominated by Checkpoint Inhibitors—But Vulnerable at Its Edges

CPI therapies remain the backbone of NSCLC treatment in patients who don’t have an actionable mutation. Collectively, the category generated approximately $50 billion in global sales in 2024, anchored by five major agents approved for NSCLC. The therapeutic concentration in lung cancer is striking:

• >30% of all NSCLC drug sales come from CPIs
• >40% of all CPI global sales originate from NSCLC alone

Merck’s Keytruda, the category-defining CPI, reported $29.5 billion in revenue in 2024, with NSCLC representing an estimated 30% of its total sales. Keytruda is expected to approach $35 billion by 2027—just before biosimilars begin entering the market in 2028.

While CPIs have transformed outcomes for some patients, in our opinion their limitations remain clear: patients without actionable mutations, and those who become CPI-refractory, still experience extremely poor prognosis and limited therapeutic benefit. We believe this treatment gap has become one of the industry’s largest unmet needs.

Telomere-Targeting: A New Pathway for a Hard-to-Treat Population

We believe that MAIA’s ateganosine represents the first drug in a new class. Unlike targeted therapies requiring EGFR, ALK, KRAS, or other mutations—and unlike immunotherapies dependent on PD-1/PD-L1 dynamics—ateganosine has been designed to exploit a universal feature of cancer cells: telomerase activity, present in more than 80% of human tumors.

Its dual mechanism has been designed to disrupt telomeres to trigger direct cancer cell death while simultaneously enabling the immune system to respond to cancer. MAIA was recently awarded Fast Track Designation by the U.S. FDA for the treatment of NSCLC in patients resistant to immunotherapy and chemotherapy, and is initiating a Phase 3 THIO-104 trial.

A Commercial Opportunity That Extends Across Oncology

With the NSCLC market now valued at $34.1 billion—projected to nearly double to $68.8 billion by 2033—the implications of a first-in-class therapy are substantial. In the United States alone, roughly 180,000 patients enter the NSCLC treatment ecosystem every year.

But ateganosine’s opportunity does not end with lung cancer. The candidate already carries FDA Orphan Drug Designations (ODDs) for:

• Glioblastoma (market: $2.2B → $3.2B growth expected)
• Hepatocellular carcinoma (HCC) (mortality: 0.8M; sales: $3.8B)
• Small cell lung cancer (SCLC) (mortality: 0.3M; sales: $2.8B)
  

Each ODD offers seven years of U.S. market exclusivity upon regulatory FDA approval and access to tax credits—advantages that strengthen MAIA’s long-term market positioning.

A Strategic Inflection Point for the Entire NSCLC Treatment Landscape

The oncology market is poised for a shift as developers seek to fill in gaps in the treatment landscape. The next decade is expected to reward novel mechanisms, and in our opinioin advanced NSCLC represents the clearest example of that gap.

Telomere-targeting therapeutics may be the next foundation in that evolution. If ateganosine’s outcomes are successful, the therapy could become a defining entrant in a space where treatment failure has long been accepted as inevitable. Statistical assessments points to a high probability of technical success for regulatory approval of ateganosine.

In our opinion, MAIA is now positioned at the center of this turning point—scientifically and strategically.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What regulatory progress did MAIA (MAIA) announce on December 10, 2025?

MAIA announced FDA Fast Track designation for ateganosine in NSCLC patients resistant to immunotherapy and chemotherapy and initiation of Phase 3 THIO-104.

How large is the NSCLC market cited in MAIA's December 10, 2025 release?

The release cites an NSCLC market value of $34.1B today, projected to $68.8B by 2033.

What commercial advantages does ateganosine have according to MAIA?

Ateganosine holds orphan drug designations for glioblastoma, HCC, and SCLC, each offering 7 years of U.S. market exclusivity upon approval.

How many U.S. NSCLC patients enter treatment annually as noted by MAIA?

MAIA cites about 180,000 U.S. patients entering the NSCLC treatment ecosystem each year.

What competitive risks did MAIA highlight that could affect NSCLC therapies?

The company noted CPI concentration led by Keytruda and that biosimilars are expected from 2028, which could affect pricing dynamics.